Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study
- 363 Downloads
This study sought to determine the multicenter reproducibility of magnetic resonance imaging (MRI) and the compatibility of different scanner platforms in assessing carotid plaque morphology and composition. A standardized multi-contrast MRI protocol was implemented at 16 imaging sites (GE: 8; Philips: 8). Sixty-eight subjects (61 ± 8 years; 52 males) were dispersedly recruited and scanned twice within 2 weeks on the same magnet. Images were reviewed centrally using a streamlined semiautomatic approach. Quantitative volumetric measurements on plaque morphology (lumen, wall, and outer wall) and plaque tissue composition [lipid-rich necrotic core (LRNC), calcification, and fibrous tissue] were obtained. Inter-scan reproducibility was summarized using the within-subject standard deviation, coefficient of variation (CV) and intraclass correlation coefficient (ICC). Good to excellent reproducibility was observed for both morphological (ICC range 0.98–0.99) and compositional (ICC range 0.88–0.96) measurements. Measurement precision was related to the size of structures (CV range 2.5–4.9 % for morphology, 36–44 % for LRNC and calcification). Comparable measurement variability was found between the two platforms on both plaque morphology and tissue composition. In conclusion, good to excellent inter-scan reproducibility of carotid MRI can be achieved in multicenter settings with comparable measurement precision between platforms, which may facilitate future multicenter endeavors that use serial MRI to monitor atherosclerotic plaque progression.
KeywordsMagnetic resonance imaging Carotid artery Atherosclerosis Reproducibility Multicenter study
This study was supported by a Grant from the Foundation for the National Institutes of Health Biomarkers Consortium made possible by funds from Merck, Pfizer, and Abbott, and by R01HL088214. Carotid coils were provided by GE Healthcare and Philips Healthcare. This manuscript represents the views of the authors and not necessarily those of the National Institutes of Health or the United States government.
Conflict of interest
Xue-Qiao Zhao reported research grants from Abbvie, Kowa, Merck, and Pfizer. Daniel S. Hippe reported grant support for analysis of unrelated data from GE Healthcare, Philips Healthcare, Society of Interventional Radiology, and RSNA Research and Education Foundation. Thomas S. Hatsukami reported research grants from Philips Healthcare. Michael T. Klimas is an employee of Merck. Robert J. Padley is an employee of Abbvie and reported stocks of Abbvie. Bradley T. Wyman was a former employee of Pfizer and reported stocks of Pfizer. Chun Yuan reported research grants from NIH, VP Diagnostics, Philips Healthcare, and consulting fees from Bristol Myers Squibb Medical Imaging and Philips Healthcare. The remaining authors reported no conflicts of interest.
- 3.Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, Kihara T, Sawada S, Iwamoto N, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F (2005) Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45:733–742PubMedCrossRefGoogle Scholar
- 4.Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, Francis JM, Jackson CE, Robson MD, Neubauer S, Channon KM, Choudhury RP (2008) Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 197:951–958PubMedCentralPubMedCrossRefGoogle Scholar
- 5.Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, Chu B, Takaya N, Liu F, Polissar NL, Neradilek B, Raichlen JS, Cain VA, Waterton JC, Hamar W, Hatsukami TS (2008) Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155:581–584CrossRefGoogle Scholar
- 7.Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C (2011) MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. J Am Coll Cardiovasc Imaging 4:977–986CrossRefGoogle Scholar
- 9.Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378:1547–1559PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Cai JM, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu BC, Takaya N, Polissar NL, Yuan C (2005) In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 112:3437–3444PubMedCrossRefGoogle Scholar
- 13.Cappendijk VC, Heeneman S, Kessels AG, Cleutjens KB, Schurink GW, Welten RJ, Mess WH, van Suylen RJ, Leiner T, Daemen MJ, van Engelshoven JM, Kooi ME (2008) Comparison of single-sequence T1w TFE MRI with multisequence MRI for the quantification of lipid-rich necrotic core in atherosclerotic plaque. J Magn Reson Imaging 27:1347–1355PubMedCrossRefGoogle Scholar
- 18.Saam T, Hatsukami TS, Yarnykh VL, Hayes CE, Underhill H, Chu BC, Takaya N, Cai JM, Kerwin WS, Xu DX, Polissar NL, Neradilek B, Hamar WK, Maki J, Shaw DW, Buck RJ, Wyman B, Yuan C (2007) Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5T Siemens, Philips, and General Electric scanners. J Magn Reson Imaging 26:344–352PubMedCrossRefGoogle Scholar
- 19.The AIM-HIGH Investigators (2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH). Am Heart J 161:471–477PubMedCentralCrossRefGoogle Scholar
- 27.Saam T, Kerwin WS, Chu BC, Cai JM, Kampschulte A, Hatsukami TS, Zhao XQ, Polissar NL, Neradilek B, Yarnykh VL, Flemming K, Huston J, Insull W, Morrisett JD, Rand SD, Demarco KJ, Yuan C (2005) Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J Cardiovasc Magn Reson 7:799–808PubMedCrossRefGoogle Scholar
- 30.Takaya N, Cai JM, Ferguson MS, Yarnykh VL, Chu BC, Saam T, Polissar NL, Sherwood J, Cury RC, Anders RJ, Broschat KO, Hinton D, Furie KL, Hatsukami TS, Yuan C (2006) Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 24:203–210PubMedCrossRefGoogle Scholar
- 31.Touze E, Toussaint JF, Coste J, Schmitt E, Bonneville F, Vandermarcq P, Gauvrit JY, Douvrin F, Meder JF, Mas JL, Oppenheim C (2007) Reproducibility of high-resolution MRI for the identification and the quantification of carotid atherosclerotic plaque components: consequences for prognosis studies and therapeutic trials. Stroke 38:1812–1819PubMedCrossRefGoogle Scholar